Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥65 years with immune thrombocytopenia

Annals of Hematology

Volumn 94, Issue 12, 2015, Pages 1973-1980

  Michel, Marc ^a   Wasser, Jeffrey ^b   Godeau, Bertrand ^a   Aledort, Louis ^c   Cooper, Nichola ^d   Tomiyama, Yoshiaki ^e   Khellaf, Mehdi ^a   Wang, Xuena ^f  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e OSAKA UNIVERSITY HOSPITAL   (Japan)

^f AMGEN INC   (United States)

Author keywords

Efficacy; Geriatric; Immune thrombocytopenia; Romiplostim; Safety; Thrombopoietin receptor agonist

Indexed keywords

PLACEBO; ROMIPLOSTIM; FC RECEPTOR; HYBRID PROTEIN; MPL PROTEIN, HUMAN; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR;

ADULT; AGED; ARTHRALGIA; ARTICLE; BLEEDING; BONE MARROW DISEASE; CONTROLLED STUDY; CONTUSION; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; ECCHYMOSIS; EPISTAXIS; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMATOMA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYALGIA; NAUSEA; PERIPHERAL EDEMA; PETECHIA; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHINOPHARYNGITIS; RISK FACTOR; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; VOMITING; AGONISTS; CHEMICALLY INDUCED; CLINICAL TRIAL; HEMORRHAGE; PHASE 3 CLINICAL TRIAL; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; HEMORRHAGE; HUMANS; INCIDENCE; MALE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; RISK FACTORS; THROMBOPOIETIN;

EID: 84944165138     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-015-2485-x     Document Type: Article

References (33)

1. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kuhne T, Ruggeri M, George JN (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113(11):2386–2393. doi:10.1182/blood-2008-07-162503
2. Fogarty PF (2009) Chronic immune thrombocytopenia in adults: epidemiology and clinical presentation. Hematol Oncol Clin North Am 23(6):1213–1221. doi:10.1016/j.hoc.2009.08.004
3. Kurata Y, Fujimura K, Kuwana M, Tomiyama Y, Murata M (2011) Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review. Int J Hematol 93(3):329–335. doi:10.1007/s12185-011-0791-1
4. Abrahamson PE, Hall SA, Feudjo-Tepie M, Mitrani-Gold FS, Logie J (2009) The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review. Eur J Haematol 83(2):83–89. doi:10.1111/j.1600-0609.2009.01247.x
5. Frederiksen H, Schmidt K (1999) The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 94(3):909–913
6. Neylon AJ, Saunders PW, Howard MR, Proctor SJ, Taylor PR (2003) Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 122(6):966–974
7. Daou S, Federici L, Zimmer J, Maloisel F, Serraj K, Andres E (2008) Idiopathic thrombocytopenic purpura in elderly patients: a study of 47 cases from a single reference center. Eur J Intern Med 19(6):447–451. doi:10.1016/j.ejim.2007.07.006
8. Guthrie TH Jr, Brannan DP, Prisant LM (1988) Idiopathic thrombocytopenic purpura in the older adult patient. Am J Med Sci 296(1):17–21
9. Linares M, Cervero A, Colomina P, Pastor E, Lopez A, Perez A, Perella M, Carbonell F (1995) Chronic idiopathic thrombocytopenic purpura in the elderly. Acta Haematol 93(2–4):80–82
10. Michel M, Rauzy OB, Thoraval FR, Languille L, Khellaf M, Bierling P, Godeau B (2011) Characteristics and outcome of immune thrombocytopenia in elderly: results from a single center case-controlled study. Am J Hematol 86(12):980–984. doi:10.1002/ajh.22170
11. Zhou H, Fu R, Wang H, Zhou F, Li H, Zhou Z, Zhang L, Yang R (2013) Immune thrombocytopenia in the elderly: clinical course in 525 patients from a single center in China. Ann Hematol 92(1):79–87. doi:10.1007/s00277-012-1567-2
12. Hu MH, Yu YB, Huang YC, Gau JP, Hsiao LT, Liu JH, Chen MH, Chiou TJ, Chen PM, Tzeng CH, Liu CY (2014) Absolute lymphocyte count and risk of short-term infection in patients with immune thrombocytopenia. Ann Hematol 93(6):1023–1029. doi:10.1007/s00277-014-2014-3
13. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovick FT, de Wolf JT, Bourgeois E, Guthrie TH Jr, Newland A, Wasser JS, Hamburg SI, Grande C, Lefrere F, Lichtin AE, Tarantino MD, Terebelo HR, Viallard JF, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol JL (2008) Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 371(9610):395–403. doi:10.1016/S0140-6736(08)60203-2
14. Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, Rodeghiero F, Chong BH, Wang X, Berger DP (2010) Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 363(20):1889–1899
15. ® (romiplostim). Full Prescribing Information, Amgen Inc., Thousand Oaks, CA, 2014
16. Olney HJ, Pabinger I, Mayer B, Bakshi K, Bailey CK, Brainsky A (2011) Efficacy and safety of eltrombopag in elderly patients with chronic immune thrombocytopenia: analysis of five clinical trials. Blood (ASH Annual Meeting Abstracts) 118:Abstract 3294
17. Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Okamoto S, Kurokawa M, Kirito K, Yonemura Y, Mori S, Usuki K, Iwato K, Hashino S, Wei H, Lizambri R (2011) Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized phase III clinical trial. Int J Hematol 94(1):71–80
18. Cines DB, Gernsheimer TB, Wasser J, Godeau B, Provan D, Lyons RM, Altomare I, Wang X, Woodard P (2012) Integrated analysis of long term safety in patients (pts) with chronic immune thrombocytopenia (ITP) treated with romiplostim. Blood (ASH Annual Meeting Abstracts) 120:Abstract 2185
19. Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, Nieva J, Wasser JS, Wiznitzer I, Kelly R, Chen CF, Nichol JL (2006) AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 355(16):1672–1681. doi:10.1056/NEJMoa054626
20. Newland A, Caulier MT, Kappers-Klunne M, Schipperus MR, Lefrere F, Zwaginga JJ, Christal J, Chen CF, Nichol JL (2006) An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 135(4):547–553. doi:10.1111/j.1365-2141.2006.06339.x
21. Kumagai Y, Fujita T, Ozaki M, Sahashi K, Ohkura M, Ohtsu T, Arai Y, Sonehara Y, Nichol JL (2007) Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: a randomized, placebo-controlled study. J Clin Pharmacol 47(12):1489–1497. doi:10.1177/0091270007306563
22. Janssens A, Tarantino MD, Bird R, Mazzucconi MG, Boccia RVV, Lopez-Fernandez MF, Kozak T, Steurer M, Te Boekhorst PAW, Dillingham K, Lizambri R (2011) Final results from an international multi-center, single-arm study evaluating the safety and efficacy of romiplostim in adults with primary immune thrombocytopenia (ITP). Blood (ASH Annual Meeting Abstracts) 118:Abstract 3279
23. Janssens A, Rodeghiero F, Anderson D, Chong B, Boda Z, Pabinger I, Cervinek L, Wang X, Lopez A (2013) Results from a phase IV open-label study evaluating changes in bone marrow morphology in adult immune thrombocytopenia (ITP) patients receiving romiplostim: analysis of the 1- and 2-year romiplostim cohorts. Blood 122 (21):Abstract 2312
24. Kuter DJ, Bussel JB, Newland A, Wasser JS, Lyons RM, George JN, Macik G, Nie K, Jun S (2013) Long-term efficacy and safety of romiplostim treatment of adult patients with chronic immune thrombocytopenia (ITP): Final report from an open-label extension study. Br J Haemat 161(3):411–423
25. Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Iwato K, Okamoto S, Kurokawa M, Kirito K, Hashino S, Ninomiya H, Mori S, Yonemura Y, Usuki K, Wei H, Lizambri R (2012) An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP). Int J Hematol 95(6):652–659
26. Kuter DJ, Mufti GJ, Bain BJ, Hasserjian RP, Davis W, Rutstein M (2009) Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood 114(18):3748–3756. doi:10.1182/blood-2009-05-224766
27. Norgaard M, Severinsen MT, Lund Maegbaek M, Jensen AO, Cha S, Sorensen HT (2012) Risk of arterial thrombosis in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol 159(1):109–111. doi:10.1111/j.1365-2141.2012.09231.x
28. Sarpatwari A, Bennett D, Logie JW, Shukla A, Beach KJ, Newland AC, Sanderson S, Provan D (2010) Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica 95(7):1167–1175. doi:10.3324/haematol.2009.018390
29. Severinsen MT, Engebjerg MC, Farkas DK, Jensen AO, Norgaard M, Zhao S, Sorensen HT (2011) Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol 152(3):360–362. doi:10.1111/j.1365-2141.2010.08418.x
30. Zoller B, Li X, Sundquist J, Sundquist K (2012) Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 379(9812):244–249. doi:10.1016/S0140-6736(11)61306-8
31. Ruggeri M, Tosetto A, Palandri F, Polverelli N, Mazzucconi MG, Santoro C, Gaidano G, Lunghi M, Zaja F, De Stefano V, Sartori R, Fazi P, Rodeghiero F, Gruppo Italiano Malattie Ematologiche Dell’Adulto (GIMEMA) Anemia and Thrombocyopenias Working Party (2014) Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. J Thromb Haemost 12(8):1266–1273. doi:10.1111/jth.12636
32. Pierrot-Deseilligny Despujol C, Michel M, Khellaf M, Gouault M, Intrator L, Bierling P, Godeau B (2008) Antiphospholipid antibodies in adults with immune thrombocytopenic purpura. Br J Haematol 142(4):638–643. doi:10.1111/j.1365-2141.2008.07228.x
33. Catala-Lopez F, Corrales I, Martin-Serrano G, Tobias A, Calvo G (2012) Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized controlled trials. Med Clin (Barc) 139(10):421–429. doi:10.1016/j.medcli.2011.11.023